PubRank

J D Lundgren

Author PubWeight™ 203.90‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006 22.76
2 Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003 7.94
3 Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998 7.53
4 Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009 4.38
5 Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008 3.68
6 Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999 3.67
7 Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007 3.58
8 HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001 2.95
9 Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002 2.90
10 Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999 2.80
11 Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000 2.49
12 An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003 2.43
13 Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet 1992 2.40
14 The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006 2.38
15 Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004 2.26
16 Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001 2.19
17 AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000 2.13
18 Update on Pneumocystis carinii f. sp. hominis typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. J Clin Microbiol 1998 2.11
19 Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004 1.98
20 Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol 1997 1.97
21 Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999 1.95
22 The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis 2013 1.91
23 Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999 1.80
24 Loss to follow-up in an international, multicentre observational study. HIV Med 2008 1.70
25 The case for indicator condition-guided HIV screening. HIV Med 2013 1.48
26 Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. AIDS in Europe Study Group. BMJ 1995 1.39
27 Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS 1993 1.36
28 A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999 1.35
29 Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005 1.34
30 Identification of Pneumocystis carinii chromosomes and mapping of five genes. Infect Immun 1990 1.34
31 Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996 1.32
32 Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis 2004 1.31
33 Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol 1998 1.31
34 Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999 1.30
35 Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med 2013 1.28
36 Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004 1.28
37 Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001 1.27
38 Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia. Chest 2001 1.21
39 Epidemiology of cryptosporidiosis among European AIDS patients. Genitourin Med 1996 1.20
40 Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther 2002 1.19
41 Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med 2007 1.17
42 Nosocomial outbreak of cryptosporidiosis in AIDS patients. BMJ 1991 1.16
43 Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. J Infect Dis 2012 1.13
44 HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med 2007 1.11
45 Antibody responses to a major Pneumocystis carinii antigen in human immunodeficiency virus-infected patients with and without P. carinii pneumonia. J Infect Dis 1992 1.09
46 Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med 2004 1.07
47 Indicator disease-guided testing for HIV--the next step for Europe? HIV Med 2008 1.05
48 Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995 1.04
49 T-cell subset alterations and lymphocyte responsiveness to mitogens and antigen during severe primary infection with HIV: a case series of seven consecutive HIV seroconverters. AIDS 1990 1.03
50 Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med 2004 1.01
51 Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in Pneumocystis carinii f.sp. hominis. AIDS 2001 1.01
52 Pretreatment with granulocyte colony-stimulating factor attenuates the inflammatory response but not the bacterial load in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. Infect Immun 1999 1.00
53 Bradykinin and respiratory mucous membranes. Analysis of bradykinin binding site distribution and secretory responses in vitro and in vivo. Am Rev Respir Dis 1990 1.00
54 Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS: a randomized European multicenter open label study. J Acquir Immune Defic Syndr 1992 0.99
55 The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS 2001 0.99
56 Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005 0.99
57 A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Med 2010 0.98
58 Transmission of Pneumocystis carinii from patients to hospital staff. Thorax 1997 0.97
59 Interleukin-8 in cerebrospinal fluid from patients with septic and aseptic meningitis. Eur J Clin Microbiol Infect Dis 1996 0.97
60 Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008 0.97
61 Heterogeneity and compartmentalization of Pneumocystis carinii f. sp. hominis genotypes in autopsy lungs. J Clin Microbiol 2001 0.96
62 Substance P and neurokinin A in human nasal mucosa. Am J Respir Cell Mol Biol 1991 0.95
63 Vasoactive intestinal peptide in human nasal mucosa. J Clin Invest 1990 0.95
64 Antibody response to a major human Pneumocystis carinii surface antigen in patients without evidence of immunosuppression and in patients with suspected atypical pneumonia. Eur J Clin Microbiol Infect Dis 1993 0.95
65 Neuropeptide Y (NPY) in human nasal mucosa. Am J Respir Cell Mol Biol 1990 0.95
66 Pneumocystis carinii major surface glycoprotein induces interleukin-8 and monocyte chemoattractant protein-1 release from a human alveolar epithelial cell line. Eur J Clin Invest 1999 0.94
67 Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 1999 0.94
68 Inhibition of leukocyte entry into the brain by the selectin blocker fucoidin decreases interleukin-1 (IL-1) levels but increases IL-8 levels in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. Infect Immun 2000 0.92
69 Independent risk of mechanical ventilation for AIDS-related Pneumocystis carinii pneumonia associated with bronchoalveolar lavage neutrophilia. Respir Med 2001 0.92
70 A sex comparison of rates of new AIDS-defining disease and death in 2554 AIDS cases. AIDS in Europe Study Group. AIDS 1994 0.92
71 Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001 0.91
72 History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Med 2010 0.90
73 Severe Rhodococcus equi pneumonia: case report and literature review. Eur J Clin Microbiol Infect Dis 1991 0.90
74 Calcitonin gene-related peptide in human nasal mucosa. Am J Physiol 1990 0.90
75 Prediction of phenotypic susceptibility to antiretroviral drugs using physiochemical properties of the primary enzymatic structure combined with artificial neural networks. HIV Med 2008 0.90
76 The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*. HIV Med 2011 0.89
77 A biobehavioural model of the night eating syndrome. Obes Rev 2009 0.89
78 The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. Am J Transplant 2013 0.89
79 Pneumocystis carinii in bronchoalveolar lavage and induced sputum: detection with a nested polymerase chain reaction. Scand J Infect Dis 1995 0.89
80 Does cytomegalovirus predict a poor prognosis in Pneumocystis carinii pneumonia treated with corticosteroids? A note for caution. Chest 1995 0.88
81 Epidemiology of tuberculosis in HIV-infected patients in Denmark. Scand J Infect Dis 1999 0.88
82 Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. AIDS 1999 0.87
83 Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group. J Clin Epidemiol 1996 0.87
84 Treatment with a monocolonal antibody to IL-8 attenuates the pleocytosis in experimental pneumococcal meningitis in rabbits when given intravenously, but not intracisternally. Clin Exp Immunol 2000 0.87
85 Virological failure among patients on HAART from across Europe: results from the EuroSIDA study. Antivir Ther 2000 0.87
86 Tuberculosis among European patients with the acquired immune deficiency syndrome. The AIDS in Europe Study Group. Tuber Lung Dis 1996 0.87
87 Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003 0.87
88 Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis 1998 0.87
89 Highly active antiretroviral therapy and coronary heart disease: the need for perspective. AIDS 2001 0.86
90 Opportunistic infections and malignancies in 231 Danish AIDS patients. AIDS 1990 0.86
91 Improved detection of Pneumocystis carinii by an immunofluorescence technique using monoclonal antibodies. Eur J Clin Microbiol Infect Dis 1990 0.86
92 Amount of Pneumocystis carinii and degree of acute lung inflammation in HIV-associated P carinii pneumonia. Chest 1993 0.85
93 Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999. HIV Med 2008 0.85
94 Influence of age on rates of new AIDS-defining diseases and survival in 6546 AIDS patients. Scand J Infect Dis 1997 0.85
95 Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med 2013 0.84
96 Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 1999 0.84
97 The major surface glycoprotein of Pneumocystis carinii induces release and gene expression of interleukin-8 and tumor necrosis factor alpha in monocytes. Infect Immun 1997 0.84
98 Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir. HIV Med 2009 0.84
99 HIV-associated lymphoma: histopathology and association with Epstein-Barr virus genome related to clinical, immunological and prognostic features. Eur J Cancer 1991 0.83
100 Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: relation to CD4 cell count and clinical course of primary infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997 0.83
101 Gastrin-releasing peptide in human nasal mucosa. J Clin Invest 1990 0.83
102 Toxoplasmosis in Danish AIDS patients. Scand J Infect Dis 1997 0.83
103 Hearing loss and cochlear damage in experimental pneumococcal meningitis, with special reference to the role of neutrophil granulocytes. Neurobiol Dis 2006 0.82
104 Trends in survival of Danish AIDS patients from 1981 to 1989. AIDS 1990 0.82
105 Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. HIV Med 2014 0.82
106 Interleukin-8 and eicosanoid production in the lung during moderate to severe Pneumocystis carinii pneumonia in AIDS: a role of interleukin-8 in the pathogenesis of P. carinii pneumonia. Respir Med 1995 0.81
107 Interleukin-8 and leukotriene B4 in bronchoalveolar lavage fluid from HIV-infected patients with bacterial pneumonia. Respir Med 1997 0.81
108 Platelet-activating factor stimulates eicosanoid production in cultured feline tracheal explants. Exp Lung Res 1992 0.81
109 Overcoming obstacles to late presentation for HIV infection in Europe. HIV Med 2010 0.81
110 Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. HIV Med 2001 0.81
111 Does European or non-European origin influence health care and prognosis for HIV patients in Europe? The EuroSIDA Study Group. HIV Med 1999 0.80
112 HIV-related non-Hodgkin's lymphoma among European AIDS patients. AIDS in Europe Study Group. AIDS in Europe Study Group. Eur J Haematol 1995 0.80
113 Hydrocortisone inhibits rat basophilic leukemia cell mediator release induced by neutrophil-derived histamine releasing activity as well as by anti-IgE. J Immunol 1991 0.80
114 Regional differences in presentation of AIDS in Europe. Epidemiol Infect 2000 0.80
115 The effects of neuropeptides on mucous glycoprotein secretion from human nasal mucosa in vitro. Neuropeptides 1992 0.80
116 A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection. HIV Med 2013 0.80
117 Prevalence of HIV infection in seronegative high-risk individuals examined by virus isolation and PCR. J Acquir Immune Defic Syndr 1991 0.80
118 Changes in use of antiretroviral therapy in regions of Europe over time. EuroSIDA Study Group. AIDS 1998 0.80
119 High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. HIV Med 2014 0.79
120 The pathophysiological role of mucus production in inflammatory airway diseases. Respir Med 1995 0.79
121 Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients. Int J Tuberc Lung Dis 2013 0.79
122 A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection 2014 0.79
123 Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998 0.79
124 The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clin Trials 2006 0.79
125 Serum type III procollagen peptide in patients with Pneumocystis carinii infection. The Copenhagen-Amsterdam PCP-Prednisolone Study Group. Am Rev Respir Dis 1993 0.79
126 Neutrophil chemotactic activity in bronchoalveolar lavage fluid of patients with AIDS-associated Pneumocystis carinii pneumonia. Scand J Infect Dis 1997 0.79
127 Human herpes virus-8 DNA in bronchoalveolar lavage samples from patients with AIDS-associated pulmonary Kaposi's sarcoma. Scand J Infect Dis 1997 0.79
128 The Pneumocystis carinii major surface glycoprotein (MSG): its potential involvement in the pathophysiology of pneumocystosis. FEMS Immunol Med Microbiol 1998 0.78
129 The outcome of Pneumocystis carinii pneumonia in Danish patients with AIDS. Scand J Infect Dis 1989 0.78
130 Penicillin as empirical therapy for patients hospitalised with community acquired pneumonia at a Danish hospital. Dan Med Bull 2001 0.78
131 Differential effect on serum neopterin and serum beta 2-microglobulin is induced by treatment in Pneumocystis carinii pneumonia. J Infect Dis 1994 0.78
132 IgM response to a human Pneumocystis carinii surface antigen in HIV-infected patients with pulmonary symptoms. Scand J Infect Dis 1993 0.78
133 Gastrin releasing peptide (GRP) binding sites in human bronchi. Neuropeptides 1992 0.78
134 Role of sensory innervation and mast cells in neurogenic plasma protein exudation into the airway lumen. Respirology 1997 0.77
135 The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study. HIV Clin Trials 2001 0.77
136 Pneumocystis carinii pneumonia in HIV-infected patients: effect of steroid therapy on surfactant level. Respir Med 1999 0.77
137 Alveolar damage in AIDS-related Pneumocystis carinii pneumonia. Chest 1997 0.77
138 Biological phenotype of HIV-1 and transmission. AIDS 1995 0.77
139 The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 2000 0.77
140 Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.77
141 Bombesin stimulates human nasal mucous and serous cell secretion in vivo. Am J Physiol 1992 0.77
142 Tumour necrosis factor and eicosanoid production from monocytes exposed to HIV in vitro. APMIS 1994 0.76
143 Effects of inhibitors of arachidonic acid metabolism on serotonin release from rat basophilic leukemia cells. Immunopharmacology 1993 0.76
144 Cytomegalovirus retinitis in patients with AIDS in Europe. AIDS in Europe Study Group. Eur J Clin Microbiol Infect Dis 1997 0.76
145 Antibody responses to Pneumocystis carinii in hospital personal with and without exposure to patients with P. carinii pneumonia. J Eukaryot Microbiol 1996 0.76
146 The role of eicosanoids in respiratory mucus hypersecretion. Ann Allergy 1985 0.76
147 Is the Salk principle still viable for the design of an effective HIV vaccine? HIV Med 2004 0.75
148 HIV remains a deadly disease. HIV Med 2004 0.75
149 [Diagnosis of Pneumocystis carinii pneumonia (PCP) in HIV-positive patients]. Ugeskr Laeger 1991 0.75
150 Rapid detection of cytomegalovirus in bronchoalveolar lavage fluid and serum samples by polymerase chain reaction: correlation of virus isolation and clinical outcome for patients with human immunodeficiency virus infection. Clin Infect Dis 1997 0.75
151 CD4 lymphocyte counts and serum p24 antigen of no diagnostic value in monitoring HIV-infected patients with pulmonary symptoms. AIDS 1990 0.75
152 [Treatment of HIV infections with antiretroviral drugs and recombinant interleukin-2]. Ugeskr Laeger 2000 0.75
153 Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. AIDS 2001 0.75
154 Evaluation of PCR technique for diagnosing Pneumocystis carinii pneumonia in HIV positive patients using oropharyngeal washings. J Eukaryot Microbiol 1996 0.75
155 Indication for fiberoptic bronchoscopy in HIV-infected patients suspected for Pneumocystis carinii pneumonia. Dan Med Bull 1990 0.75
156 Effects of gastrin-releasing peptide and analogues on guinea pig nasal mucosal secretion. Am J Physiol 1993 0.75
157 Human neutrophil-derived histamine-releasing activity (HRA-N) causes the release of serotonin but not arachidonic acid metabolites from rat basophilic leukemia cells. J Allergy Clin Immunol 1992 0.75
158 Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study. Scand J Infect Dis 1999 0.75
159 The whole-mount method as a technique for measuring experimental changes in airway goblet cell number. APMIS 1989 0.75
160 [Heterosexual transmission of HIV in Denmark in 2001. A real risk or a negligible problem?]. Ugeskr Laeger 2001 0.75
161 [Pneumocystis carinii pneumonia in HIV-infected patients examined by bronchoscopy during the period 1989-1991]. Ugeskr Laeger 1994 0.75
162 [Prognostic value of interleukin-8 in AIDS-related Pneumocystis carinii pneumonia]. Ugeskr Laeger 1996 0.75
163 Comparison of human nasal mucosal secretion in vivo and in vitro. J Allergy Clin Immunol 1992 0.75
164 [The Society of Theoretical and Applied Therapy. The medal of honour for the year of 2000]. Ugeskr Laeger 2000 0.75
165 [Lung disease and HIV infection]. Ugeskr Laeger 1989 0.75
166 European contribution to the science, prevention and management of HIV infection. Vaccine 1997 0.75
167 [Heterosexual HIV infection in Denmark. Observations from an infectious disease department]. Ugeskr Laeger 1990 0.75
168 Effect of protein kinase C activating agents on respiratory glycoconjugate release from feline airways. Am J Physiol 1991 0.75
169 When to start and stop? HIV Med 2001 0.75
170 [Acute infection with human immune deficiency virus]. Ugeskr Laeger 1988 0.75